Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1Not yet recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Observational 1Interventional 1

Sponsor

Conditions

Myasthenia Gravis 2

Interventions

pembrolizumab 168Carboplatin 137Cisplatin 85Paclitaxel 81Gemcitabine 79Pemetrexed 75Bevacizumab 65Docetaxel 56Fluorouracil 50Oxaliplatin 49Dexamethasone 47durvalumab 43atezolizumab 40Leucovorin 40130-nm albumin-bound paclitaxel 40Capecitabine 38Cetuximab 36Rituximab 35Nivolumab 35Fulvestrant 35Cyclophosphamide 34Injections 31venetoclax 29Lenalidomide 29Prednisone 28enzalutamide 27Letrozole 26pomalidomide 25Irinotecan 25daratumumab 22

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × ravulizumab × 30 days × Clear all
NCT07596784 2026-05-19

Efficacy and Safety of Ravulizumab in Chinese Adults Participants With Generalized Myasthenia Gravis (gMG)

Alexion Pharmaceuticals, Inc.

Phase 3 Not yet recruiting
20 enrolled

Myasthenia Gravis

NCT06909253 2026-05-15

MG-ARCADIA

AstraZeneca

Recruiting
50 enrolled

Myasthenia Gravis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡